Matrigel improved murine wound repair, while hPMSCs added a smaller histologic gain
Impaired cutaneous healing remains a stubborn problem because excess inflammation can derail the tightly timed sequence of matrix deposition, re-epithelialization, and tissue remodeling. In this preclinical study, investigators tested whether a Matrigel scaffold, human placenta-derived mesenchymal stromal cells (hPMSCs), or the two together could improve repair in full-thickness excisional wounds in female BALB/c mice. Two wounds were created on the dorsum of each animal, and separate cohorts were examined on days 7, 14, and 21 after injury. The design allowed a side-by-side look at scaffold effects, cell effects, and their combination, but it also left an important gap: no non-MSC cellular control was included to separate the influence of the delivery matrix from the biological identity of the cells.
The repair signal was visible in histology. By day 21, collagen density reached 86.1 ± 7.5% in the hPMSC + Matrigel group, compared with 77.8 ± 6.6% for Matrigel alone, 68.4 ± 5.1% for hPMSCs alone, and 45.1 ± 4.1% for vehicle control. In practical terms, the scaffold carried much of the effect. Across the three time points, the improvement in collagen density with Matrigel alone was already 80–93% as large as the combination-versus-vehicle difference when the group means were compared descriptively. The added contribution from hPMSCs was measurable but modest: 5.8, 3.8, and 8.3 percentage points at days 7, 14, and 21, respectively, with statistical significance after Bonferroni adjustment preserved only at day 7.
Scaffold effects dominated the collagen signal
A dermal substitute can change the wound environment in several ways at once. Matrigel is not just a passive filler; it provides a three-dimensional matrix that supports cell attachment, preserves growth factors, and may stabilize the early wound bed long enough for fibroblasts and keratinocytes to organize a more coherent repair response. In this model, that biology appears to have mattered. The Matrigel-alone arm consistently outperformed vehicle, and the combination arm produced the highest collagen density of all groups at every time point reported.
The combination also produced the most organized dermal architecture and the highest re-epithelialization grade on qualitative assessment at day 21. Those findings matter because collagen quantity alone does not guarantee functional repair. A wound can deposit matrix rapidly yet remain disorganized, stiff, or poorly epithelialized. Here, the histologic picture suggested not just more collagen, but a more orderly repair trajectory when cells were embedded in the scaffold rather than delivered alone.
One sentence captures the central result plainly: the scaffold mattered more than the cells did.
Re-epithelialization and matrix organization tracked with the combined arm
The study used histologic and histomorphometric analysis rather than serial wound-area photography. That choice shifts the emphasis away from surface closure kinetics and toward tissue quality. Re-epithelialization was graded on a five-point ordinal scale, and collagen density was quantified morphometrically from Masson’s trichrome-stained sections. Inflammatory cell infiltration and skin appendage regeneration were described qualitatively, not counted, which keeps the interpretation anchored to tissue structure rather than to a complete cellular census.
This distinction is important when thinking about wound healing therapies. A treatment can alter the early inflammatory phase, the matrix phase, or the epithelial phase, yet a single readout rarely captures the whole process. In this case, the combination of hPMSCs and Matrigel appeared to favor the downstream structural consequences of repair. The best histologic result at day 21 fit with a wound bed that had likely entered a more stable regenerative phase, though the study did not directly measure local angiogenesis, fibroblast activity, or immune-cell phenotype in the wound itself.
Serum cytokines shifted, but the wound microenvironment was not directly measured
Systemic immune markers moved in a direction compatible with immunomodulation. hPMSC administration was associated with higher serum IL-10 and lower IFN-γ relative to control, while IL-17 changed little. On a mechanistic level, that pattern is biologically plausible for a cell therapy proposed to temper inflammation: IL-10 is associated with anti-inflammatory signaling, while IFN-γ can reflect a more pro-inflammatory, Th1-skewed environment. Reduced systemic inflammatory tone could help limit collateral tissue injury and make matrix remodeling more efficient.
Still, the serum data should not be overread. No local wound-bed immunologic analysis was performed, so the cytokine changes remain an association rather than proof of a local mechanism. The study also did not quantify inflammatory cells or assess angiogenesis directly. As a result, the work supports a systemic immunologic signal alongside histologic repair, but it does not demonstrate how much of the observed benefit came from altered inflammation, altered paracrine signaling, altered scaffold biology, or some combination of the three.
What the preclinical signal does and does not support
The strongest preclinical message is straightforward: Matrigel improved histologic wound repair relative to vehicle, and adding hPMSCs produced a small additional histologic gain, with the combined condition performing best overall. Yet the study design leaves an unavoidable interpretive boundary. Without a non-MSC cellular control, the incremental value of the cells cannot be pinned specifically to hPMSC identity. Without local wound microenvironment analysis, the cytokine shift cannot be translated into a demonstrated mechanism at the wound site. Without serial wound-area measurements, the work cannot say whether the histologic improvements translated into faster macroscopic closure.
Even so, the data point to a plausible translational idea: a living cell therapy may perform better when delivered inside a matrix that protects the cells and supports early tissue organization. In chronic or complicated wounds, the clinical challenge is rarely one pathway alone. The wound bed is shaped by inflammation, matrix turnover, oxygenation, and epithelial migration at the same time. A scaffold can create structure; stromal cells may contribute paracrine signals that dampen inflammation and encourage repair. This study offers an early preclinical example of that pairing, while also showing how much work remains before the approach can be treated as more than a histologic proof of concept.
The next step is not a larger claim. It is a tighter experiment with a true cellular comparator, direct wound-bed biology, and functional closure data.